mScarlet/LUC Reporter Cell Line - ID8

The ID8 cell line is a highly characterized murine model of ovarian carcinoma, originally derived from the spontaneous malignant transformation of ovarian surface epithelial cells isolated from C57BL/6 mice. It is a cornerstone in gynecological oncology, highly valued as a syngeneic model that faithfully replicates the complex tumor microenvironment and disease progression characteristic of advanced human ovarian cancer. The mScarlet/Luc Reporter Cell Line - ID8 is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both the exceptionally bright, monomeric red fluorescent protein mScarlet and firefly luciferase (Luc). This advanced dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental epithelial morphology, the intrinsic biological properties, or the highly tumorigenic capacity of the original parental ID8 cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the ID8 model for comprehensive translational ovarian cancer research. For in vitro studies, the distinct mScarlet expression provides intense red fluorescence, allowing researchers to easily visualize cellular dynamics, accurately quantify proliferation rates, and seamlessly isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase activity serves as the optimal foundation for non-invasive, longitudinal tracking of primary tumor progression and widespread peritoneal dissemination through bioluminescence imaging (BLI). Because it is a murine-derived cell line, the ID8-mScarlet/Luc model is engrafted into immunocompetent, syngeneic C57BL/6 mice to establish clinically relevant orthotopic intrabursal models or robust models of peritoneal carcinomatosis and ascites accumulation. This specialized reporter line represents an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of novel chemotherapeutic regimens, targeted pharmacological compounds, and—crucially—emerging immunotherapies (such as immune checkpoint inhibitors), facilitating the real-time, accurate quantification of localized tumor burden and disseminated disease in living subjects with fully intact immune systems.